ライフサイエンスコーパス: IUdR

1 IUdR and metabolites were measured in venous blood sampl

2 *IUdR can be prepared instantly, by either demercuration

3 In addition, [123I]IUdR has a potential role in the scintigraphic detection

4 After locoregional administration, [123I]IUdR and [125I]IUdR localize within tumor, clear rapidly

5 ng [123I]IUdR and currently using both [123I]IUdR and [125I]IUdR.

6 e analog 5-[123I]iodo-2'-deoxyuridine ([123I]IUdR).

7 n emitters has antineoplastic effects ([123I]IUdR and [125I]IUdR) in addition to its scintigraphic po

8 with several concentrations of either [123I]IUdR or [125I]IUdR and their colony survival was measure

9 The Do dose rates for [123I]IUdR and [125I]IUdR, respectively, are 18.78 and 1.88 in

10 after intra-arterial administration of [123I]IUdR in patients with liver metastases and intravesicula

11 The pharmacokinetics of [123I]IUdR locoregionally administered to a human glioma in si

12 dition to its scintigraphic potential ([123I]IUdR and [131I]IUdR), it holds promise for therapy and e

13 ith bladder carcinoma, initially using [123I]IUdR and currently using both [123I]IUdR and [125I]IUdR.

14 with a cystic glioma was injected with [123I]IUdR.

15 sibly by imaging later than 24 h after [124I]IUdR administration.

16 on of 28.0-64.4 MBq (0.76-1.74 mCi) of [124I]IUdR in 20 patients with brain tumors, including meningi

17 The plasma half-life of [124I]IUdR was short (2-3 min), and the arterial plasma input

18 lity of 5-[(125)I]iodo-2'-deoxyuridine ((125)IUdR)-labeled tumor cells to exert a damaging effect on

19 present within and/or released from the (125)IUdR-labeled cells.

20 Iodine-125-IUdR was infused intracerebrally over a 2-day period int

21 th the Auger electron emitter 123I or 125I (*IUdR).

22 ith the Auger electron emitter 123I or 125I, IUdR demonstrates therapeutic efficacy.

23 egional administration, [123I]IUdR and [125I]IUdR localize within tumor, clear rapidly from the rest

24 antineoplastic effects ([123I]IUdR and [125I]IUdR) in addition to its scintigraphic potential ([123I]

25 The Do dose rates for [123I]IUdR and [125I]IUdR, respectively, are 18.78 and 1.88 initial decays/ce

26 nd currently using both [123I]IUdR and [125I]IUdR.

27 All patients had [125I]IUdR and [131I]IUdR uptake in tumor, with a biexponentia

28 patients were each infused with 5 mCi [125I]IUdR and 10 mCi [131I]IUdR through the sideport of a hep

29 tumor cell after an infusion of 5 mCi [125I]IUdR.

30 re treated for 5 days with 18.5 kBq/ml [125I]IUdR.

31 There is persistent uptake of [125I]IUdR in hepatic tumors, thereby making hepatic artery in

32 with which to quantify the fraction of [125I]IUdR incorporated within the DNA of tumor cells.

33 pigs after multiple administrations of [125I]IUdR into the aorta, carotid artery and bladder.

34 concentrations of either [123I]IUdR or [125I]IUdR and their colony survival was measured.

35 When [125I]IUdR is used as a therapeutic agent, we anticipate littl

36 Patients were injected with [125I]IUdR through the hepatic artery.

37 After incubation with [125I]IUdR, selective eradication of HeLa cells from a co-cult

38 and grown for 7 days in medium without [125I]IUdR.

39 Iodine-131-IUdR was used as a tracer for imaging and quantitation.

40 UdR by demercuration whereby [123I/125I/131I]IUdR is synthesized virtually instantaneously following

41 cted therapeutic trial to evaluate[125I/131I]IUdR pharmacokinetics in liver metastases from colorecta

42 All patients had [125I]IUdR and [131I]IUdR uptake in tumor, with a biexponential clearance.

43 cintigraphic potential ([123I]IUdR and [131I]IUdR), it holds promise for therapy and early diagnosis

44 fused with 5 mCi [125I]IUdR and 10 mCi [131I]IUdR through the sideport of a hepatic artery pump.

45 tumor development (hyperplasia stage); (3) *IUdR was able to penetrate deep within the bladder wall;

46 from the tissue during the 24-h period after IUdR injection.

47 but with a range of a few cell diameters, an IUdR analogue labeled with 211At could markedly improve

48 caffeine enhanced IUdR-DNA incorporation and IUdR-mediated radiosensitization by partially inhibiting

49 As IUdR is rapidly dehalogenated by the liver, the intraven

50 e agents (IR, IUdR, and caffeine) as well as IUdR or caffeine combined with IR are less or equally ef

51 rtaken to determine the relationship between IUdR concentration and the duration of radiolabeled IUdR

52 the SUV and Tm:Br ratio values reflect both IUdR-DNA incorporated and exchangeable nonincorporated r

53 antigens but did not appear to be induced by IUdR treatment.

54 whereas SERV sequences were also induced by IUdR.

55 n), and rats bearing either bladder cancer (*IUdR by intravesical injection), brain gliosarcomas (int

56 dual mode of radiosensitization by combining IUdR and caffeine-like drugs (e.g., UCN-01) in p53-defic

57 rent cell cycle states and the corresponding IUdR-DNA incorporation at a particular time point.

58 he thymidine analogue 5-iodo-2'deoxyuridine (IUdR) is highly cytotoxic but only to cells going throug

59 peutic potential of 5-iodo-2'- deoxyuridine (IUdR) radiolabeled with the Auger electron emitters 123I

60 he thymidine analog, 5-iodo-2'-deoxyuridine (IUdR), is incorporated in the DNA of cells in the S phas

61 ine (AzaC) and with 5'-iodo-2'-deoxyuridine (IUdR); none was detected with sodium butyrate.

62 on of radiolabeled 5-iodo-2'- deoxyuridine (*IUdR) is accomplished by iododemetallation.

63 We found that caffeine enhanced IUdR-DNA incorporation and IUdR-mediated radiosensitizat

64 Estimates for IUdR-DNA incorporation in tumor tissue (Ki) required pha

65 The D(o) dose for *IUdR can be determined from survival curves versus the m

66 of silver grains (i.e., no DNA-incorporated *IUdR).

67 the cell cycle for the purpose of increasing IUdR-mediated radiosensitivity in MMR(-) cells.

68 We instilled *IUdR for 2 hr directly within the bladder lumen of rats

69 ates the total transformation of iodide into IUdR with no detectable UV-absorbing by-products.

70 Iododeoxyuridine (IUdR) uptake and retention was imaged by positron emissi

71 eases dramatically upon 5'-iododeoxyuridine (IUdR) treatment, (iv) lacZ expression is induced with th

72 5-Iododeoxyuridine (IUdR) and caffeine are recognized as potential radiosens

73 colon cancer cells with 5-iododeoxyuridine (IUdR).

74 emphasis of radiolabeled iododeoxyuridine (*IUdR) research at our institution to date has been to as

75 genic survival, the three single agents (IR, IUdR, and caffeine) as well as IUdR or caffeine combined

76 ange Auger electrons emitted by 125I-labeled IUdR can cause double-strand breaks, delivering a lethal

77 ntration at 1/2 Vmax (K) is 3.717 x 10(-6) M IUdR.

78 n, an inhibition of uptake by 10 micrometers IUdR, and the incorporation of about 50% of cell-bound a

79 hat MMR(-) cells incorporate 25% to 42% more IUdR than MMR(+) cells, and that IUdR and ionizing radia

80 s of radiolabeled (125I) and nonradiolabeled IUdR and the mole rate of IUdR incorporation in double-s

81 al tissues by predicting the optimal dose of IUdR and optimal timing for IR treatment to increase the

82 rsus MMR(+) cells to describe the effects of IUdR incorporation upon the cell cycle for the purpose o

83 The incorporation of IUdR into DNA of CHO cells, although the sum of a series

84 d in the bladder, there is little leakage of IUdR in the circulation.

85 ort the conditions for the radiosynthesis of IUdR by destannylation of the tributylstannyl precursor

86 The maximum rate of IUdR incorporation (Vmax) is 4.424 x 10(-18) mol/min and

87 nd nonradiolabeled IUdR and the mole rate of IUdR incorporation in double-stranded DNA was measured.

88 by partially inhibiting repair (removal) of IUdR in DNA.

89 t MMR is involved in the repair (removal) of IUdR-DNA, principally the G:IU mispair.

90 m survival curves versus the mole amount of *IUdR incorporated in DNA.

91 arget cells incorporate a cytocidal dose of *IUdR.

92 be a kit formulation for the preparation of *IUdR by demercuration whereby [123I/125I/131I]IUdR is sy

93 er, ARG demonstrated that (1) the uptake of *IUdR was observed in the hyperplastic and carcinomatous

94 However, these effects of caffeine on IUdR-mediated radiosensitization were not found in p53-p

95 These models can be combined to predict IUdR-DNA incorporation at any time in the cell cycle.

96 ncentration and the duration of radiolabeled IUdR treatment required to incorporate the equivalent of

97 trated that the distribution of radiolabeled IUdR was mainly confined to the tumor (injection site),

98 to 42% more IUdR than MMR(+) cells, and that IUdR and ionizing radiation (IR) interact to produce up

99 tment it will be necessary to manipulate the IUdR delivery time, concentration and volume in a manner

100 e bearing an intraperitoneal ovarian tumor (*IUdR by intracavitary injection), and rats bearing eithe

101 cient cells, particularly when combined with IUdR.

102 d to the carcinogen but were instilled with *IUdR.

103 n cancer cell lines treated with and without IUdR.